Baidu
map

Blood:补充IL-2可改善特发性再生障碍性贫血患者预后

2020-05-01 MedSci原创 MedSci原创

FasL介导的细胞凋亡在AA的Treg耗竭和亚群失衡中起重要作用,可导致免疫失调。 残余的AA treg对高浓度IL-2产生FasL抗性,并在炎症环境中发挥作用。

特发性再生障碍性贫血(AA)具有两个主要特点:针对造血干细胞/祖细胞的自身免疫反应和调节性T细胞(Tregs)缺陷。研究人员既往已经证明了在AA患者的Treg的一个特定亚群减少,该亚群可以预测患者对免疫抑制治疗的反应性。本研究旨在明确Treg亚群失衡的机制,并确定治疗干预的潜力。

目前,研究人员已经确定了两种导致AA患者Treg组成混乱的机制。一、FasL介导的配体相互作用的凋亡;二、IL-2的相对剥夺。

现研究人员已证实IL-2增多可克服这些机制。有趣的是,将高浓度的IL-2加入体外培养的Treg时,AA患者来源的Treg可进行扩增。扩增的细胞表达高水平的p-BCL2;p-BCL2使它们对凋亡耐受。

研究人员进一步通过移植瘤小鼠模型来检测扩增的AA Tregs细胞的功能和稳定性,发现这些Tregs细胞能够抑制T细胞介导的移植物抗宿主病的宏观临床特征和组织表现。这些Treg在高炎症环境中维持其抑制特性和表型。

本研究结果为深入了解AA中Treg细胞减少的机制提供了思路,明确了具有治疗干预潜力的新靶点。在常规免疫抑制治疗的基础上,补充具有高浓度IL-2的Treg体外扩增培养物或直接予以IL-2可改善AA患者的临床疗效。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1692128, encodeId=27e7169212806, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Jun 29 02:05:14 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896308, encodeId=8a828963086e, content=<a href='/topic/show?id=c5c230692d8' target=_blank style='color:#2F92EE;'>#再生障碍性贫血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30692, encryptionId=c5c230692d8, topicName=再生障碍性贫血)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 02 16:47:40 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894771, encodeId=c9de1894e71e0, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Aug 13 22:05:14 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029241, encodeId=c7e02029241b7, content=<a href='/topic/show?id=5d5c6e868b3' target=_blank style='color:#2F92EE;'>#特发性再生障碍性贫血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67868, encryptionId=5d5c6e868b3, topicName=特发性再生障碍性贫血)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Sun Jul 26 10:05:14 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626058, encodeId=2c0d162605834, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sun May 03 13:05:14 CST 2020, time=2020-05-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1692128, encodeId=27e7169212806, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Jun 29 02:05:14 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896308, encodeId=8a828963086e, content=<a href='/topic/show?id=c5c230692d8' target=_blank style='color:#2F92EE;'>#再生障碍性贫血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30692, encryptionId=c5c230692d8, topicName=再生障碍性贫血)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 02 16:47:40 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894771, encodeId=c9de1894e71e0, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Aug 13 22:05:14 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029241, encodeId=c7e02029241b7, content=<a href='/topic/show?id=5d5c6e868b3' target=_blank style='color:#2F92EE;'>#特发性再生障碍性贫血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67868, encryptionId=5d5c6e868b3, topicName=特发性再生障碍性贫血)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Sun Jul 26 10:05:14 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626058, encodeId=2c0d162605834, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sun May 03 13:05:14 CST 2020, time=2020-05-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1692128, encodeId=27e7169212806, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Jun 29 02:05:14 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896308, encodeId=8a828963086e, content=<a href='/topic/show?id=c5c230692d8' target=_blank style='color:#2F92EE;'>#再生障碍性贫血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30692, encryptionId=c5c230692d8, topicName=再生障碍性贫血)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 02 16:47:40 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894771, encodeId=c9de1894e71e0, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Aug 13 22:05:14 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029241, encodeId=c7e02029241b7, content=<a href='/topic/show?id=5d5c6e868b3' target=_blank style='color:#2F92EE;'>#特发性再生障碍性贫血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67868, encryptionId=5d5c6e868b3, topicName=特发性再生障碍性贫血)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Sun Jul 26 10:05:14 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626058, encodeId=2c0d162605834, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sun May 03 13:05:14 CST 2020, time=2020-05-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1692128, encodeId=27e7169212806, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Jun 29 02:05:14 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896308, encodeId=8a828963086e, content=<a href='/topic/show?id=c5c230692d8' target=_blank style='color:#2F92EE;'>#再生障碍性贫血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30692, encryptionId=c5c230692d8, topicName=再生障碍性贫血)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 02 16:47:40 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894771, encodeId=c9de1894e71e0, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Aug 13 22:05:14 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029241, encodeId=c7e02029241b7, content=<a href='/topic/show?id=5d5c6e868b3' target=_blank style='color:#2F92EE;'>#特发性再生障碍性贫血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67868, encryptionId=5d5c6e868b3, topicName=特发性再生障碍性贫血)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Sun Jul 26 10:05:14 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626058, encodeId=2c0d162605834, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sun May 03 13:05:14 CST 2020, time=2020-05-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1692128, encodeId=27e7169212806, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Mon Jun 29 02:05:14 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896308, encodeId=8a828963086e, content=<a href='/topic/show?id=c5c230692d8' target=_blank style='color:#2F92EE;'>#再生障碍性贫血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30692, encryptionId=c5c230692d8, topicName=再生障碍性贫血)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 02 16:47:40 CST 2020, time=2020-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894771, encodeId=c9de1894e71e0, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Thu Aug 13 22:05:14 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029241, encodeId=c7e02029241b7, content=<a href='/topic/show?id=5d5c6e868b3' target=_blank style='color:#2F92EE;'>#特发性再生障碍性贫血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67868, encryptionId=5d5c6e868b3, topicName=特发性再生障碍性贫血)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Sun Jul 26 10:05:14 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626058, encodeId=2c0d162605834, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sun May 03 13:05:14 CST 2020, time=2020-05-03, status=1, ipAttribution=)]
    2020-05-03 tomyang93

相关资讯

Nature:创新IL-2模拟蛋白,有望成为癌症免疫疗法新武器

日前,美国华盛顿大学的研究人员在《自然》杂志上发表的科学论文表示,该团队构建了一款合成蛋白,它能够模拟IL-2的作用,而且可以避免与IL-2相关的毒副作用,这一合成蛋白有望成为有力的癌症免疫疗法。

赛诺菲宣布将以25亿美元收购Synthorx,以增强其肿瘤免疫学业务

赛诺菲与Synthorx已达成最终协议,根据该协议,赛诺菲将以每股68美元的现金收购Synthorx的所有流通股,相当于总股本价值约25亿美元(按完全稀释后的价值)。

Sci Signal:IL-2信号通路对自身免疫疾病的影响

调节性T细胞 (regulatory T cells, Treg) 能够抑制对自体产生反应的效应T细胞,从而防止诸如1型糖尿病这类自身免疫疾病的产生。而白细胞介素-2 (interleukin-2, IL-2) 对Treg细胞不同亚型的发育和在体内的动态平衡非常重要。

J Gerontol A Biol Sci Med Sci:IL-6水平升高可导致老人谵妄的发生?

对术后患者的研究表明,炎症因子水平的升高与患者谵妄的发生相关。谵妄是一种严重的精神错乱,往往发生在老年人术后或者身患重大疾病的时候。目前,由贝斯以色列女执事医疗中心(BIDMC)所进行的一项新的研究证实,炎症(身体遭受有害刺激时机体的一种保护性免疫反应)在谵妄的发生中起重要作用,该研究成果发表于The Journals of Gerontology, Series A: Biological Sc

Diabetes:IL-2受体在1型糖尿病中发挥中枢性作用

近日,一项发表在Diabetes杂志上的一则研究"Central role for interleukin-2 in type 1 diabetes"证实IL-2在1型糖尿病中的关键性作用。 1型糖尿病临床表现为显著高血糖症,由进展性免疫介导的胰岛β细胞损伤及相关代谢功能障碍引起。如今遗传与免疫联合研究突出白细胞介素-2 (IL-2) 受体及其下游信号传导通路缺陷1型糖尿病发病机制中的中枢缺

Baidu
map
Baidu
map
Baidu
map